Most recent update: Friday, November 15, 2019 - 09:33

Bariatric News - Cookies & privacy policy

You are here

Treating adolescent obesity

Treating adolescent obesity - the evidence behind the options

The authors argue bariatric surgery is an effective treatment for adolescents with severe obesity

As rates of adolescent obesity continue to rise, choice of treatment needs to be guided by the severity of obesity, psychosocial factors, comorbidities and patient's age and pubertal status, according to a paper published in the Journal of the American Medical Association.

"Rather than proceeding by chronological stages or phases, treatment should occur as an integrated continuum of care that begins with the least invasive, yet appropriately intensive treatment," writes author, Dr Michelle Cardel of the University of Florida College of Medicine in Gainseville. "All options should be discussed with the family, and it is critical to use patient-first language and terms preferred by adolescents, such as BMI, and to avoid terms such as fat." Co-authors of the paper included Dr Ania Jastreboff Mof Yale University School of Medicine in New Haven, CN, and Dr Aaron Kelly, University of Minnesota Center for Pediatric Obesity Medicine in MN.

In the paper, ‘Treatment of Adolescent Obesity in 2020’, Cardel and colleagues address the evidence behind behavioural intervention, pharmacological and weight loss options. For the behavioural intervention, the study's authors recommend delivery of at least 26 contact hours over two to 12 months by an interdisciplinary team including a paediatrician, registered dietician, exercise physiologist and/or psychologist. Targeting the home environment may facilitate change, and involving the family is recommended. Changing one's diet to decrease portion sizes, consume less ultra-processed foods, sugar-sweetened beverages and other added sugars; eating more fruits, vegetables, and fibre; and eating meals with the family is also recommended.

On the pharmacological side, the FDA has approved two medications for adolescent obesity: orlistat, a lipase inhibitor for long-term use and phentermine, a norepinephrine and a reuptake inhibitor for short term use. In the largest randomised clinical trial, takers of orlistat experienced mild to moderate gastrointestinal problems. No randomised clinical trials of phentermine have been conducted in individuals younger than 17 years of age.

"Filling the treatment gap between lifestyle modification therapy and bariatric surgery should be prioritized. Medications can help address the gap but we need to accelerate the pace of research evaluating the safety and efficacy of anti-obesity agents for children and adolescents," said Kelly.

The authors argue bariatric surgery is an effective treatment for adolescents with severe obesity. The TEEN Longitudinal Assessment of Bariatric Surgery (TEEN-LABS) reported a three-year mean BMI reductions of 29 percent with Roux-en-Y gastric bypass and 27 percent with vertical sleeve gastrectomy among individuals aged 19 years or younger. The five-year outcomes in the Roux-en-Y gastric bypass group demonstrated that the BMI reduction was largely sustained. The authors said long-term safety and effectiveness data in patients undergoing bariatric surgery during adolescence is lacking.

"Cardel and her co-authors have done a nice job summarising the therapeutic options for adolescents with obesity. However, because almost 21 percent of adolescents aged 12-19 years have obesity, the challenge is not what to do, but how to do it,” said Dr William Dietz, Past President of The Obesity Society and Director of the Sumner M Redstone Global Center for Prevention and Wellness at the Milken Institute of Public Health at George Washington University in Washington, DC. “While primary care physicians are appropriately the frontline responders, the time required for joint decision-making with patients and the lack or reimbursement pose major obstacles to care.”

"As obesity medicine physicians and clinical providers we strive to provide the safest, most effective care across the lifespan for all patients with obesity. It is essential for us to approach each patient with compassion and understanding, supporting and guiding them through their life-long journey to better health," said Jastreboff.

Regarding to conflict of interest disclosures, Cardel reports receiving grants from the National Insitutes of Health (NIH) during the conduct of the study. Jastreboff reported receiving personal fees from and serving as consultant for Novo Nordisk, Rhythm Pharmaceuticals, and Medtronic Diabetes. Kelly reported serving as unpaid advisor to Novo Nordisk, Vivus, Orexigen, Takeda and WW, and receiving research support from AstraZeneca for an NIH-funded clinical trial.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.